Method for administering glp-1 molecules

Abstract

The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.

1 .- 5 . (canceled) 
     
     
         6 . A method of treating a subject suffering from obesity comprising orally administering an effective amount of a solid oral pharmaceutical composition comprising
 (a) a GLP-1 compound, wherein the GLP-1 compound is a GLP-1 derivative of a naturally occurring GLP-1 polypeptide; and   (b) a delivery agent of the formula   
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The method of  claim 6 , wherein the delivery agent is a sodium salt of 
       
         
           
           
               
               
           
         
       
     
     
         8 . The method of  claim 6 , wherein the GLP-1 compound is a GLP-1 derivative comprising a polypeptide of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:14. 
     
     
         9 . The method of  claim 8 , wherein the delivery agent is a sodium salt of 
       
         
           
           
               
               
           
         
       
     
     
         10 . A method of treating a subject suffering from non-insulin dependent diabetes comprising orally administering an effective amount of a solid oral pharmaceutical composition comprising
 (a) a GLP-1 compound, wherein the GLP-1 compound is a GLP-1 derivative of a naturally occurring GLP-1 polypeptide; and   (b) a delivery agent of the formula   
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         11 . The method of  claim 10 , wherein the delivery agent is a sodium salt of 
       
         
           
           
               
               
           
         
       
     
     
         12 . The method of  claim 10 , wherein the GLP-1 compound is a GLP-1 derivative comprising a polypeptide of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:14. 
     
     
         13 . The method of  claim 12 , wherein the delivery agent is a sodium salt of 
       
         
           
           
               
               
           
         
       
     
     
         14 . A solid oral pharmaceutical composition comprising
 (a) a GLP-1 compound, wherein the GLP-1 compound is a GLP-1 derivative of a naturally occurring GLP-1 polypeptide; and   (b) a delivery agent of the formula   
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         15 . The solid oral pharmaceutical composition of  claim 14 , wherein the delivery agent is a sodium salt of 
       
         
           
           
               
               
           
         
       
     
     
         16 . The solid oral pharmaceutical composition of  claim 14 , wherein the GLP-1 compound is a GLP-1 derivative comprising a polypeptide of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:14. 
     
     
         17 . The solid oral pharmaceutical composition of  claim 16 , wherein the delivery agent is a sodium salt of